Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

INTRA-CELLULAR THERAPIES, INC.

(ITCI)
  Report
Delayed Nasdaq  -  04:00 2022-12-02 pm EST
54.08 USD   +1.18%
11/10Intra-Cellular Therapies to Participate at Two Upcoming Investor Conferences
AQ
11/04RBC Lifts Price Target on Intra-Cellular Therapies to $69 From $67, Maintains Outperform Rating
MT
11/03Intra-Cellular Therapies Reports Narrower Q3 Loss, Higher Revenue; Shares Jump
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Goldman Sachs Lowers Intra-Cellular Therapies' Price Target to $64 From $71, Maintains Buy Rating

08/10/2022 | 10:29am EST


ę MT Newswires 2022
All news about INTRA-CELLULAR THERAPIES, INC.
11/10Intra-Cellular Therapies to Participate at Two Upcoming Investor Conferences
AQ
11/04RBC Lifts Price Target on Intra-Cellular Therapies to $69 From $67, Maintains Outperfor..
MT
11/03Intra-Cellular Therapies Reports Narrower Q3 Loss, Higher Revenue; Shares Jump
MT
11/03Transcript : Intra-Cellular Therapies, Inc., Q3 2022 Earnings Call, Nov 03, 2..
CI
11/03Intra-cellular : Q3 Earnings Snapshot
AQ
11/03INTRA-CELLULAR THERAPIES, INC. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDI..
AQ
11/03Intra-Cellular Therapies, Inc. Reports Earnings Results for the Third Quarter and Nine ..
CI
11/03Intra-cellular Therapies, Inc. : Results of Operations and Financial Condition, Other Even..
AQ
11/03Earnings Flash (ITCI) INTRA-CELLULAR THERAPIES Posts Q3 Revenue $71.9M
MT
11/03Intra-Cellular Therapies Reports Third Quarter 2022 Financial Results and Provides Corp..
AQ
More news
Analyst Recommendations on INTRA-CELLULAR THERAPIES, INC.
More recommendations
Financials (USD)
Sales 2022 248 M - -
Net income 2022 -271 M - -
Net cash 2022 271 M - -
P/E ratio 2022 -18,8x
Yield 2022 -
Capitalization 5 122 M 5 122 M -
EV / Sales 2022 19,5x
EV / Sales 2023 11,1x
Nbr of Employees 512
Free-Float 97,4%
Chart INTRA-CELLULAR THERAPIES, INC.
Duration : Period :
Intra-Cellular Therapies, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INTRA-CELLULAR THERAPIES, INC.
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 13
Last Close Price 54,08 $
Average target price 68,58 $
Spread / Average Target 26,8%
EPS Revisions
Managers and Directors
Sharon Mates Chairman, President & Chief Executive Officer
Lawrence J. Hineline Chief Financial Officer, Treasurer & SVP-Finance
Robert E. Davis Chief Scientific Officer & Senior Vice President
Suresh Durgam Chief Medical Officer & Senior Vice President
Karen Patruno Sheehy Chief Compliance Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
INTRA-CELLULAR THERAPIES, INC.3.32%5 122
VERTEX PHARMACEUTICALS46.34%82 493
REGENERON PHARMACEUTICALS, INC.20.54%81 852
BIONTECH SE-34.16%41 250
WUXI APPTEC CO., LTD.-34.47%32 173
GENMAB A/S24.60%30 178